Negative Wealth Shock Linked to Accelerated Cognitive Decline
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Dec. 26, 2023 -- For older adults, negative wealth shock is associated with accelerated cognitive decline and increased risks for dementia, according to a study published online Dec. 26 in JAMA Network Open.
Liulu Pan, from the Zhejiang University School of Medicine in Hangzhou, China, and colleagues used data from the Health and Retirement Study conducted among U.S. adults older than 50 years to examine whether negative wealth shock is associated with cognitive decline and incident dementia. The final sample included 8,082 participants.
The researchers found that 1,441 participants developed incident dementia during a median follow-up of 14 years. Participants with negative wealth shock had accelerated cognitive decline (β coefficient, −0.014) and an increased risk for dementia (hazard ratio, 1.27) compared with those who had positive wealth without shock. Participants with asset poverty at baseline also had higher dementia risks (hazard ratio, 1.61). Associations were significant for White participants and those younger than 65 years (hazard ratios, 1.34 and 1.38, respectively), but not for those of other races and ethnicities or those aged 65 years or older.
"The negative wealth shock-associated dementia risks were more apparent among White participants and those who were younger," the authors write. "Further prospective and interventional studies are warranted to confirm our findings."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2023-12-27 04:15
Read more
- Exposure to Inorganic Arsenic in Drinking Water Increases Cardiovascular Risk
- Patient-Reported Lumbar Symptom Information Beneficial for Radiologists
- Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
- Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma
- Transitioning to E-Cigarettes Aids Resolution of Respiratory Symptoms
- Ozempic, Wegovy Could Help Ease Knee Arthritis Pain
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions